Aurinia Pharmaceuticals Inc (STU:IKAP)
€ 9.252 -0.386 (-4%) Market Cap: 1.32 Bil Enterprise Value: 1.07 Bil PE Ratio: 0 PB Ratio: 3.73 GF Score: 84/100

Aurinia Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 04, 2021 / 07:10PM GMT
Release Date Price: €11.43 (-2.81%)
Kenneth Charles Cacciatore
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Okay. Great. Thanks, everyone, for joining the Aurinia fireside. We're really happy to have today with us Peter, Neil, Max and Glenn. Thanks for taking the time. You're in the midst of real busy time, exciting time for the company with the launch. So we're appreciative of having you guys for at least a half an hour here.

With that, Peter, why don't we turn it over to you see if you have any opening comments or thoughts?

Peter S. Greenleaf
Aurinia Pharmaceuticals Inc. - President, CEO & Director

Ken, first and foremost, on behalf of the company, I want to thank Cowen and yourself and your team for having us here today. Obviously, it's an exciting time for the company. I mean we've gone through the last 2 years pushing our way through Phase III data and a positive outcome in our lupus nephritis trial after years of work, post the acquisition of the asset from the original founders of the company. And that rolled into a busy year of NDA filing,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot